Skip to main content

Table 3 Odds ratios and 95 % confidence intervals for the associations between total, n-6 and n-3 polyunsaturated fatty acids and incident end-stage renal disease in a case–control study nested within the Southern Community Cohort Study

From: Dietary polyunsaturated fatty acids and incidence of end-stage renal disease in the Southern Community Cohort Study

Fatty acid

Quintilesa

P for trend

1 (Lowest)

2

3

4

5 (Highest)

Total PUFA

 ESRD cases

208

207

233

212

214

 

 Median, % energy

5.8

7.1

8.0

8.8

10.2

 

 Model 1

1.00

1.00 (0.80–1.25)

1.18 (0.95–1.47)

1.04 (0.83–1.30)

1.04 (0.84–1.31)

0.63

 Model 2

1.00

0.94 (0.73–1.20)

0.99 (0.77–1.27)

0.80 (0.62–1.04)

0.76 (0.59–0.99)

0.02

 Model 3b

1.00

0.94 (0.73–1.21)

1.01 (0.78–1.32)

0.85 (0.65–1.12)

0.79 (0.60–1.05)

0.06

n-6 PUFA

 ESRD cases

205

217

235

206

211

 

 Median, % energy

5.62

6.89

7.70

8.52

9.79

 

 Model 1

1.00

1.08 (0.87–1.35)

1.22 (0.98–1.52)

1.02 (0.82–1.28)

1.04 (0.84–1.31)

0.88

 Model 2

1.00

1.02 (0.80–1.31)

1.02 (0.79–1.31)

0.80 (0.62–1.04)

0.78 (0.60–1.01)

0.01

 Model 3b

1.00

1.02 (0.80–1.32)

1.03 (0.80–1.34)

0.85 (0.64–1.11)

0.81 (0.61–1.06)

0.04

n-3 PUFA

 ESRD cases

223

204

207

208

232

 

 Median, % energy

0.01

0.03

0.05

0.08

0.15

 

 Model 1

1.00

0.89 (0.72–1.11)

0.91 (0.73–1.13)

0.91 (0.73–1.14)

1.06 (0.85–1.32)

0.66

 Model 2

1.00

0.90 (0.71–1.14)

0.85 (0.67–1.08)

0.86 (0.67–1.10)

0.92 (0.71–1.19)

0.38

 Model 3b

1.00

0.89 (0.70–1.14)

0.85 (0.67–1.09)

0.86 (0.67–1.11)

0.93 (0.71–1.21)

0.45

  1. Abbreviations: ESRD End-stage renal disease, PUFA Polyunsaturated fatty acids
  2. aValues are odds ratios and corresponding 95 % confidence intervals from models in which total, n-6 and n-3 PUFA were modeled separately. Model 1 included matching variables (age, sex and race), total energy intake and quintiles of energy from total PUFA or n-3 PUFA or n-6 PUFA. Model 2 additionally adjusted for diabetes and percent energy from protein intake. Model 3 additionally adjusted for body mass index, hypertension, education level, household income, smoking status and percent energy from saturated fat intake
  3. bIn a sensitivity analysis among 1,574 participants with eGFR ≥60 mL/min/day (180 cases and 1394 controls), further adjusting for eGFR did not change the results appreciably. For example, in analyses adjusting for eGFR and covariates in model 3 and using the lowest quintile as the referent, the ORs (95 % CIs) for ESRD in the 2nd, 3rd, 4th and 5th quintile of total PUFA were 0.90 (0.485, 1.69), 1.32 (0.71, 2.46), 1.44 (0.75, 2.75) and 0.90 (0.47, 1.74), respectively. The corresponding OR (95 % CIs) for n-6 PUFA were 0.79 (0.42, 1.47), 1.26 (0.68, 2.30), 1.11 (0.58, 2.14) and 0.82 (0.43, 1.57) while they were 0.93 (0.53, 1.61), 0.55 (0.30, 1.02), 0.72 (0.40, 1.31) and 1.02 (0.56, 1.86) for n-3 PUFA
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us